United States: Capitol Hill Healthcare Update - February 13, 2017

At HHS, Price will lead Trump's efforts on ACA repeal

Three weeks into President Trump's administration, the Senate on Friday narrowly approved Tom Price as Secretary of the U.S. Department of Health and Human Services (HHS), elevating the former orthopedic surgeon as Trump's point person on repealing and replacing the Affordable Care Act (ACA). Price won Senate confirmation 52-47 after Democrats exhausted all procedural tools to block a vote. No Democrat voted to confirm Price.

Price's installation is key to Republicans' drive to repeal the healthcare law. Because much of the ACA was implemented through department regulation, Price will determine which provisions can be dialed back or wiped out altogether by withdrawing existing HHS regulations, promulgating new ones or simply not enforcing what's already on the books.

The Secretary's first regulatory action may be to bolster the ACA, not undermine it. Congressional staff say HHS may push changes that would favor insurers – by allowing them to charge older customers higher premiums – in an effort to keep insurance companies from abandoning the ACA marketplaces before Congress can agree on an overall replacement plan. 

ACA taxes unsettled as GOP struggles on repeal plans

President Trump said Friday that he was putting together "the final strokes" of an ACA replacement plan, but congressional Republicans are working methodically on what would follow an ACA repeal, and House Speaker Paul Ryan said legislating on a replacement plan could take all year.

While key Republicans say they want to immediately repeal the ACA's taxes on wealthy individuals and providers, there are continuing indications that the issue isn't settled. Some GOP lawmakers, including the No. 2 Senate Republican, Sen. John Cornyn (R-Texas), say Congress will need access to that tax revenue both to fund the ACA during the transition and for whatever policy follows it. 

Republicans still plan to repeal most of the ACA using legislation known as budget reconciliation, which Democrats can't derail with a filibuster in the Senate. GOP leaders want the repeal bill to include elements of their replace plans, including expanded Health Savings Accounts and tax credits to aid people buying insurance. Congress would later debate a series of individual bills that collectively would finish out their plans on what would follow the ACA.

But underscoring the Republican division over how to proceed, a leading conservative, Sen. Mike Lee, (R-Utah), said last week that no ACA replacement provisions should be included in the bill to repeal the law. "If we load down the repeal discussion with what comes next, I think it's going to make it a lot harder to get either one of them done," Lee said during a forum at the conservative Heritage Foundation.

The timing for approving repeal of the ACA in reconciliation legislation appears to be slipping too. Several House committees were slated to draft components during the week of Feb. 27, but that has been delayed into March as leaders seek to educate and gain support from lawmakers on details. The GOP leadership will hold listening sessions this week with House rank-and-file members to discuss health savings accounts and potential Medicaid changes.

With committee action delayed, it is possible Congress won't pass a final reconciliation bill repealing most of the ACA until April, when insurers will begin to formulate 2018 rates for policies sold next year on the ACA exchanges.

Senate panel to hold hearing on CMS pick

The Senate Finance Committee on Thursday will hold a hearing on Seema Verma's nomination to be administrator of the Centers for Medicare and Medicaid Services (CMS). Verma, who founded a healthcare consulting firm, worked to expand Indiana's Medicaid program when Vice President Pence was that state's governor. She also consulted with several other Republican governors on their Medicaid programs. Committee Chairman Orrin Hatch (R-Utah) praised Verma's "extensive background and depth of experience in health policy," saying she's "immensely qualified" to lead CMS. Although Senate Democrats have been fighting most of President Trump's Cabinet picks, it's not clear whether that would extend to agencies like CMS. So far Verma hasn't triggered any public criticism from Democrats.

House FDA user fee hearings delayed

The House Energy and Commerce Committee has delayed for several weeks consideration of legislation reauthorizing $2 billion in industry user fees to the FDA. Drug and medical device manufacturers agreed with the FDA last year on a new five-year user fee agreement, and the FDA held a series of public hearings on the deal. Congress has until Sept. 30 to renew the user fees though lawmakers want to act before that.

The committee had planned hearings this week, beginning with the medical device industry agreement. But the committee pushed back the hearings until March and is expected to begin with the generic drug user fee agreement. The Senate is also expected to begin its user fee hearings next month.

Energy and Commerce Committee Chairman Greg Walden (R-Ore.) said he wants the user fee package voted on by the House sometime in May. Congressional leaders want to shield the reauthorization from related healthcare controversies, like prescription drug prices. It is likely that any changes or amendments to the underlying user fee legislation would need significant bipartisan support to be included in the reauthorization.

House Democrat to talk drug prices with Trump

Rep. Elijah Cummings (D-Md.) said he will meet with President Trump at the White House this week to discuss prescription drug costs. Cummings had been invited to a meeting with Trump and pharmaceutical CEOs last week but was conflicted from attending. The long-time Baltimore lawmaker has been an outspoken critic of the drug industry, which he has accused of raising drug prices only to increase company profits.

Trump repeatedly pledged during last year's campaign to require Medicare to negotiate drug prices with manufacturers, a change in law that would require congressional approval. In the meeting with CEOs, however, the president backed off, focusing instead on speeding approval of generic drugs. But White House spokesman Sean Spicer walked that back the next day, reaffirming Trump's position that Medicare should be allowed to negotiate directly with pharmaceutical companies over drug prices.

Grassley questions orphan drug exclusivity

Senate Judiciary Committee Chairman Chuck Grassley (R-Iowa) said his office is examining what role a law designed to incentivize development of treatments for rare diseases may be playing in the overall costs of prescription drugs. The Senator said he wanted to know whether pharmaceutical manufacturers were abusing the Orphan Drug Act by repurposing drugs approved for wider audiences to narrower populations with rare diseases. Under the 1983 law, drugs approved to treat fewer than 200,000 patients include tax credits and seven years of marketing exclusivity. 

Grassley said his staff would meet with stakeholders to understand whether "orphan drug provisions appear to be stretched beyond their original intent." The Senator didn't announce whether he would push for Senate hearings or put a timetable on his review.

Separately, Rep. Peter Welch (D-Vt.) introduced legislation last week that would limit the 340B drug discount program's orphan drug exclusion by applying it only when drugs are used to treat the rare diseases or conditions they were first approved to treat.

Pence backs legislation on "right to try"

Vice President Pence last week endorsed legislation that would give terminally ill patients wider access to prescription drugs that haven't yet won FDA approval.

Sen. Ron Johnson (R-Wis.) introduced bipartisan legislation last month that would permit patients access to unapproved drugs if their doctors certify no other treatment options exist. Identical legislation was introduced in the House last week by Reps. Andy Biggs (R-Ariz.) and Brian Fitzpatrick (R-Pa.). The bills would go beyond current FDA policy of approving single-patient access to experimental treatments with physician and drug company approval.

Pence also supported so-called right-to-try legislation as Indiana governor. The Vice President met with patient advocates last week and announced his support of the federal legislation. Pharmaceutical manufacturers have resisted similar legislation in Congress and the states, saying early access to unapproved drugs could give patients false hope and also threaten the integrity of ongoing clinical trials if those patients have adverse reactions. 

GOP leaders to choose Price successor on key panel

House Republican leaders are scheduled to meet Tuesday to choose a GOP lawmaker to take the coveted seat of former Rep. Tom Price (R-GA) on the Ways and Means Committee. An opening on the powerful panel became available when Price resigned from the House last week after he was sworn in as HHS secretary. While several House Republicans are vying for the slot, GOP leaders are expected to choose Rep. Mike Bishop (R-Mich.). In addition to jurisdiction over tax policy, the committee has authority over CMS and Medicare Part A and Part B.

"Cures" authors seek guidance on FDA hiring freeze

The two principal authors of last year's "21st Century Cures" medical innovation law are asking the White House for clarification on whether President Trump's federal hiring freeze affects the FDA. Even before President Trump issued the executive order on January 23 freezing all new government hires, the FDA had nearly 1,000 positions unfilled. The government-wide freeze is only exacerbating workload concerns at the FDA, according to Reps. Fred Upton (R-Mich.) and Diane DeGette (D-Colo.).

The lawmakers, in a letter to the Office of Management and Budget (OMB), said the freeze could impact FDA commitments made under current industry user fee agreements as well as new funds Congress appropriated last year to hire additional FDA staff under the Cures law. The lawmakers called on OMB to issue guidance clarifying whether the FDA is subject to the hiring freeze. Several senators also have called on the White House to spell out whether the FDA might be exempt from the executive order.

Bipartisan bill would expand "Sunshine" reporting

Sens. Chuck Grassley (R-Iowa) and Richard Blumenthal (D-Conn.) last week reintroduced legislation extending current reporting requirements under the Sunshine Act to include payments made to physician assistants, nurse practitioners and other advanced practice nurses. Both senators have pushed the legislation since 2015, but it has not received a vote to date. Grassley was the principal author of the Sunshine Act, which was enacted as part of the ACA in 2010.

With Republicans focused on repeal of the ACA, Grassley will fight any attempt to remove or weaken its existing sunshine provisions. But it's uncertain whether the Republican-controlled Congress has the appetite to expand reporting requirements as Grassley wants. Most providers oppose expanding the law, saying it won't improve data collection but would burden providers with additional paperwork requirements. Already a significant percentage of payments or transfers currently reported under the law include low-cost meals and refreshments provided with training programs.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions